Cover Image
市場調查報告書

退行性寡樹突膠質細胞瘤:全球臨床實驗趨勢

Anaplastic Oligoastrocytoma Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 296842
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
退行性寡樹突膠質細胞瘤:全球臨床實驗趨勢 Anaplastic Oligoastrocytoma Global Clinical Trials Review, H1, 2017
出版日期: 2017年03月31日 內容資訊: 英文 111 Pages
簡介

本報告提供退行性寡樹突膠質細胞瘤的治療藥相關臨床實驗調查分析,提供您臨床實驗數及受驗人數,各階段及各期狀況,有潛力的企業,開發中的治療藥資訊,臨床實驗簡介等相關的系統性資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 主要國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:退行性寡樹突膠質細胞瘤臨床實驗數量佔腫瘤臨床實驗數量比率

各期臨床實驗數量:G7各國

G7各國的臨床實驗數量:各期

E7各國的臨床實驗數量:退行性寡樹突膠質細胞瘤臨床實驗數量佔腫瘤臨床實驗數量比率

各期臨床實驗數量:E7各國

E7各國的臨床實驗數量:各期

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參與企業 - 退行性寡樹突膠質細胞瘤治療藥

有潛力的藥劑

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GlobalData's clinical trial report, "Anaplastic Oligoastrocytoma Global Clinical Trials Review, H1, 2017" provides an overview of Anaplastic Oligoastrocytoma clinical trials scenario. This report provides top line data relating to the clinical trials on Anaplastic Oligoastrocytoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Anaplastic Oligoastrocytoma to Oncology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Anaplastic Oligoastrocytoma to Oncology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Anaplastic Oligoastrocytoma Therapeutics Clinical Trials 29
  • Prominent Drugs 31
  • Clinical Trial Profile Snapshots 32

Appendix 108

  • Abbreviations 108
  • Definitions 108
  • Research Methodology 109
  • Secondary Research 109
  • About GlobalData 110
  • Contact Us 110
  • Disclaimer 110
  • Source 111

List of Tables

  • Anaplastic Oligoastrocytoma Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Anaplastic Oligoastrocytoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Anaplastic Oligoastrocytoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
  • Proportion of Anaplastic Oligoastrocytoma to Oncology Clinical Trials, G7 Countries (%), 2017* 15
  • Anaplastic Oligoastrocytoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Anaplastic Oligoastrocytoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Anaplastic Oligoastrocytoma to Oncology Clinical Trials, E7 Countries (%), 2017* 18
  • Anaplastic Oligoastrocytoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Anaplastic Oligoastrocytoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Anaplastic Oligoastrocytoma Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Anaplastic Oligoastrocytoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Anaplastic Oligoastrocytoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Anaplastic Oligoastrocytoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
  • Anaplastic Oligoastrocytoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31

List of Figures

  • Anaplastic Oligoastrocytoma Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Anaplastic Oligoastrocytoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Anaplastic Oligoastrocytoma Therape
Back to Top